In the phase 3 trial Roche novel drug has demonstrated statistically significant and clinically meaningful overall survival rate compared with palbociclib and fulvestrant alone. Read more: https://pharma.economictimes.indiatimes.com/news/research-and-development/roches-itovebi-shows-positive-survival-rate-in-advance-stage-breast-cancer/117629216